MIRA Pharmaceuticals (NASDAQ: MIRA) — Perfil da empresa, notícias e dados financeiros
MIRA Pharmaceuticals develops innovative treatments for various diseases, targeting unmet medical needs in the biotech sector.

MIRA Pharmaceuticals
MIRA Pharmaceuticals (NASDAQ:MIRA) is a dynamic player in the biotechnology sector, focused on developing innovative treatments to address unmet medical needs. The company's operations span from early-stage research to clinical trials, with projects targeting a variety of diseases. MIRA Pharmaceuticals aims to revolutionize patient care through groundbreaking therapies, leveraging the latest scientific discoveries and a highly skilled team. Their portfolio includes potential treatments for rare diseases, chronic conditions, and life-threatening illnesses, underscoring their commitment to improving health outcomes worldwide. With a forward-thinking approach, MIRA Pharmaceuticals strives to lead the way in biopharmaceutical advancements, ensuring better and more accessible treatments for patients around the globe.
Resumo
Operações
Produtos e/ou serviços de MIRA Pharmaceuticals
- Development of innovative oncology drugs targeting resistant cancer cells.
- Research on personalized medicine approaches for effective cancer treatments.
- Advanced diagnostic tools for early detection of various cancers.
- Collaboration on biotechnological advancements in gene therapy.
- Manufacturing high-quality, affordable generic medications for widespread health issues.
- Provision of specialized consulting services to healthcare providers on drug management and patient care.
equipe executiva do MIRA Pharmaceuticals
- Erez AminovCEO & Chairman
- Andriy MushakChief Financial Officer
- Itzchak AngelChief Scientific Advisor
Últimas notícias sobre a MIRA Pharmaceuticals
MIRA submits Ketamir-2 trial protocol
United StatesMIRA Pharmaceuticals reports positive preclinical data for Mira-55
United StatesMIRA Pharmaceuticals submits Phase 2a protocol for Ketamir-2
United StatesMIRA Pharmaceuticals consolidates global rights for pipeline candidates MIRA-55 and SKNY-1
United States
Principais indicadores financeiros
Resultados divulgados pela MIRA Pharmaceuticals , em USD.
- Cap. de mercado
- 23,4 mi
- Receita (TTM)
- 0
- P/L
- —
- LPA (diluído, TTM)
- -1.2
- Dividend yield
- —
- Margem de lucro
- 0.0%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 0 | -10,5 mi | -10,4 mi | |
| 0 | -8 mi | -7,9 mi | |
| 0 | -8,5 mi | -12 mi | |
| 0 | -7 mi | -7,1 mi |